ABEO
Price
$5.01
Change
-$0.26 (-4.93%)
Updated
Feb 4, 02:16 PM (EDT)
Capitalization
286.13M
47 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$5.70
Change
-$0.30 (-5.00%)
Updated
Feb 4, 02:22 PM (EDT)
Capitalization
415.17M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABEO vs BCYC

Header iconABEO vs BCYC Comparison
Open Charts ABEO vs BCYCBanner chart's image
Abeona Therapeutics
Price$5.01
Change-$0.26 (-4.93%)
Volume$3.1K
Capitalization286.13M
Bicycle Therapeutics
Price$5.70
Change-$0.30 (-5.00%)
Volume$100
Capitalization415.17M
ABEO vs BCYC Comparison Chart in %
ABEO
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABEO vs. BCYC commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and BCYC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ABEO: $5.27 vs. BCYC: $6.00)
Brand notoriety: ABEO and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 80% vs. BCYC: 269%
Market capitalization -- ABEO: $286.13M vs. BCYC: $415.17M
ABEO [@Biotechnology] is valued at $286.13M. BCYC’s [@Biotechnology] market capitalization is $415.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileBCYC’s FA Score has 1 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, ABEO is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 5 TA indicator(s) are bullish while BCYC’s TA Score has 3 bullish TA indicator(s).

  • ABEO’s TA Score: 5 bullish, 3 bearish.
  • BCYC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than BCYC.

Price Growth

ABEO (@Biotechnology) experienced а +3.13% price change this week, while BCYC (@Biotechnology) price change was -15.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

ABEO is expected to report earnings on Mar 23, 2026.

BCYC is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($415M) has a higher market cap than ABEO($286M). ABEO YTD gains are higher at: 0.000 vs. BCYC (-15.254). ABEO has higher annual earnings (EBITDA): 89.8M vs. BCYC (-245.86M). BCYC has more cash in the bank: 648M vs. ABEO (207M). BCYC has less debt than ABEO: BCYC (5.74M) vs ABEO (24.1M). BCYC has higher revenues than ABEO: BCYC (28.3M) vs ABEO (400K).
ABEOBCYCABEO / BCYC
Capitalization286M415M69%
EBITDA89.8M-245.86M-37%
Gain YTD0.000-15.254-
P/E Ratio4.36N/A-
Revenue400K28.3M1%
Total Cash207M648M32%
Total Debt24.1M5.74M420%
FUNDAMENTALS RATINGS
ABEO vs BCYC: Fundamental Ratings
ABEO
BCYC
OUTLOOK RATING
1..100
103
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1596
PRICE GROWTH RATING
1..100
6079
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (15) in the null industry is somewhat better than the same rating for ABEO (75) in the Pharmaceuticals Generic industry. This means that BCYC’s stock grew somewhat faster than ABEO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that BCYC’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (15) in the Pharmaceuticals Generic industry is significantly better than the same rating for BCYC (96) in the null industry. This means that ABEO’s stock grew significantly faster than BCYC’s over the last 12 months.

ABEO's Price Growth Rating (60) in the Pharmaceuticals Generic industry is in the same range as BCYC (79) in the null industry. This means that ABEO’s stock grew similarly to BCYC’s over the last 12 months.

ABEO's P/E Growth Rating (98) in the Pharmaceuticals Generic industry is in the same range as BCYC (100) in the null industry. This means that ABEO’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOBCYC
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PCSV0.120.01
+7.82%
PCS Edventures!.com, Inc.
EMLAF34.610.91
+2.70%
Empire Ltd.
CRARF21.76N/A
N/A
Credit Agricole SA
CBAOF1.94N/A
N/A
CIBanco SA CTF Bursatiles Fiduciarios Inmobiliario
AMJT1.32N/A
N/A
AMJ Global Technology

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with RGNX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+1.93%
RGNX - ABEO
44%
Loosely correlated
+0.74%
OCUL - ABEO
43%
Loosely correlated
-6.99%
AURA - ABEO
43%
Loosely correlated
+1.02%
AUTL - ABEO
42%
Loosely correlated
N/A
DYN - ABEO
42%
Loosely correlated
+1.07%
More

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with NRIX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-7.55%
NRIX - BCYC
53%
Loosely correlated
-1.76%
NGNE - BCYC
51%
Loosely correlated
-4.20%
SYRE - BCYC
51%
Loosely correlated
+1.65%
RLAY - BCYC
48%
Loosely correlated
+6.38%
SLDB - BCYC
47%
Loosely correlated
+1.71%
More